
What happened
BioInvestGPT's July simulation of Derdelsiran predicted no significant efficacy in late-stage trials; Novartis's stock fell 11% and $30 billion in market value was erased.
Why it matters
So far 5 of BioInvestGPT's 6 predictions have been correct, suggesting AI simulations may help pharma partners screen which drug programs to advance or value as acquisition targets.
WHO IT HITSPharma R&D and business-development teams evaluating which drug programs to fund, partner on, or acquire are the most direct audience, since the body says AI simulations are already used to spot programs worth advancing and to value acquisition targets.
Summaries like this, in your inbox every morning.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Nvidia-backed AI data centre operator Firmus withdrew its planned $5 billion IPO on Friday, citing market vola…

Google released Google AI Edge Foresight, a free macOS Labs app that uses EmbeddingGemma 2 and Gemma 4 to tran…

CoreWeave launched CoreWeave Forge, connecting serving, observability, post-training and evaluation
Samsung Electronics' next-generation 12-layer HBM4E high-bandwidth memory has reportedly cleared customer qual…

Kelsey Kuan, general manager of HD Renewable Energy subsidiary Star Trade, told DIGITIMES that energy storage…

Google Cloud announced Gemini Agent, a cloud-based multi-agent tool
